Enzyme. This retention of records may be extended if there is a legal proceeding pending (i.e., court action, or US interference or opposition involving the Intellectual Property) where those records are reasonably required and a written request with the reason is provided to the Party. Nothing herein shall require, or be construed to require, that DIVERSA disclose to DOW any DIVERSA Know-How, except to the extent necessary for the filing of patent applications [*****]. DOW shall not be required to disclose to DIVERSA any DOW Know-How or any DOW [*****] on any Research [*****], Research [*****] or [*****] Enzyme, except for the reasonable information required by the RMC.
Enzyme. 7.4.2 During the Term, within [***] after the end of each Calendar Year, Merck shall deliver to Codexis a written notice identifying each (a) Fee Bearing Therapeutic Product and the Merck Developed API contained within each Fee Bearing Therapeutic Product and (b) Therapeutic Product (and the Merck Developed API contained within each such Therapeutic Product) that (i) is in active development by Merck, its Affiliates or a permitted licensee or assign and (ii) is being evaluated or has been evaluated in a Phase III Clinical Trial. During the Term, Codexis may from time to time request from Merck to confirm to Codexis whether a specific Therapeutic that (i) is in active development by Merck, its Affiliates or a permitted licensee or assign and (ii) is being evaluated or has been evaluated in a Phase III Clinical Trial is manufactured using an Enzyme, and Merck will respond in writing within a reasonable time to such written request from Codexis.
Enzyme. The enzyme is [**]. ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. Schedule 1.47 Partner Territory The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & Xxxxxxxxxxx, Xxxxxxx, Xxxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxxxx, Xxxxxxx, Xxxxxx & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. Schedule 3.2 Clinical Trials Dupuytren’s Disease [**] Peyronie’s Disease [**] Frozen Shoulder [**] ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST. Schedule 13.1 Notice to BTC BioSpecifics Technologies Corp. 00 Xxxxxx Xxxxxx Lynbrook, New York 11563 Attention: Xxxxxx Xxxxxx, President Dear Xxx: In connection with the Amended and Restated Development and License Agreement (the “ License Agreement”) between us, dated as of December , 2008, we wish to confirm to you as follows:
Enzyme. 1.1.1 Purity *** > 92 %
Enzyme. Schedule 1.2.1 Enzyme The enzyme is [**]. ** CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED PURSUANT TO AN ORDER GRANTING CONFIDENTIAL TREATMENT ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION. Schedule 3.2 Clinical Trials Schedule 3.2 Clinical Trials Dupuytren’s Disease [**] Peyronie’s Disease [**]
Enzyme. 1.81 “Merck Exclusive Field” means the research, development, and manufacture of Covered Enzymes and Enzymes for use in the animal and/or human healthcare field solely by Merck and its Affiliates, or on behalf of Merck and its Affiliates in accordance with Section 3.2, in the chemical synthesis of Therapeutic Products owned or Controlled by Merck (including, for clarity, the chemical synthesis of Merck Developed APIs for formulation into any Therapeutic Controlled by Merck), but excluding, in any event, the discovery of any Therapeutic Enzyme, Diagnostic, or Vaccine. 1.82 “Merck Initial Enzyme(s)” means any enzyme (which for clarity is not an “Enzyme”) that is provided by Merck and which is designated as an Initial Enzyme pursuant to a Technology Transfer Project excluding, for clarity, Enzymes derived from a Codexis Enzyme or a Codexis Library. 1.83 “Merck Non-Exclusive Field” means the research, development, and manufacture of Covered Enzymes and Enzymes for use solely by Merck and its Affiliates, or on behalf of Merck and its Affiliates in accordance with Section 3.2, for Internal Research Purposes, but excluding, in any event, the discovery of any Therapeutic Enzyme, Diagnostic, or Vaccine, or any sale, lease, license, transfer or use of such Covered Enzymes or Enzymes as a standalone product or a component of a product. 1.84 “Merck Project Library” means any collection, set or sub-set of Enzymes and/or expression vectors containing genes that encode for Enzymes derived from a Technology Transfer Project. 1.85 “Option Improvements” means all Improvements relating to the Platform Technology, including, without limitation, Codexis Core Technology Improvements (including any and all Improvements to the Codexis Methods, the Initial Technology Transfer Inventory and the Codexis [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. - 10 – Execution Version Software), Improvements to the Codexis Materials and/or the Codexis Documentation, which have come to be Controlled by Codexis during the applicable Option Year. 1.86 “Option Year” means each of the [***] twelve (12)-month periods commencing with the day immediately following the TT Term Expiration Date and thereafter commencing with each anniversary thereof. For clarity, the [***]. 1.87 “Patent(s)” means (a) patents and patent applications anywhere in the ...
Enzyme of Batches Required Batches purchased [***] Price per Batch Total Price Outstanding - [***] -------- --------------- --------------- ----------- ------------------- Lipase [***] [***] [***] [***] Protease [***] [***] [***] [***] Amylase [***] [***] [***] [***] [***] ENZYME # of Batches [***]Batch [***] Pricing Remaining Batches at purchased in [***] Requirement Requirement [***] pricing ------------------ ----------- ------------- -------------------- Lipase [***] [***] [***] [***] Protease [***] [***] [***] [***] Amylase [***] [***] [***] [***] Please note in this example that the total of Batches purchased in [***] is CHF [***].
Enzyme. The enzyme is [***]. *** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. Schedule 1.47 Partner Territory The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & Xxxxxxxxxxx, Xxxxxxx, Xxxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxxxx, Xxxxxxx, Xxxxxx & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. Schedule 3.2 Clinical Trials Dupuytren’s Disease [***] Peyronie’s Disease [***] Frozen Shoulder [***] *** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. Schedule 13.1 Notice to BTC BioSpecifics Technologies Corp. 00 Xxxxxx Xxxxxx Lynbrook, New York 11563 Attention: Xxxxxx Xxxxxx, President Dear Xxx: In connection with the Amended and Restated Development and License Agreement (the " License Agreement") between us, dated as of December __, 2008, we wish to confirm to you as follows:
Enzyme. The enzyme is collagenase obtained by fermentation of Clostridium histolyticum, purified by chromatography, lyophilized and substantially free from other proteinases. SCHEDULE 3.2 CLINICAL TRIALS SCHEDULE 3.2 CLINICAL TRIALS DUPUYTREN'S DISEASE Dupy 303a and Dupy 303b Double Blind, Randomized, Placebo Controlled Sxxxx of the Rexxxxve Safety and Efficacy of Collagenase Therapy in the Treatment of Residual Type Dupuytren's Disease 11/21/03 Dupy 299 An Open Label Training Study for the Use of Collagenase Theraxx xor the Use of Collagenase Therapy in the Treatment of Residual Type Dupuytren's Disease 4/4/03 Dupy 404 An Open Label Study of the Relative Safety and Efficacy of Coxxxxenase Therapy in the Treatment of Residual Type Dupuytren's Disease 4/4/03 PEYRONIE'S DISEASE
Enzyme. Next * projected sales of Ceredase(R) and Cerezyme(R) is based upon Genzyme's * amount for Nova Factor with Nova Factor's agreement but that in no event will be less than the * unless agreed to by Genzyme.
